Duke Physician Highlights Positive Ovarian Cancer Clinical Trial Results
Angeles Alvarez Secord, MD, presented promising data on mirvetuximab soravtansine (MIRV) for platinum-sensitive ovarian cancer (PROC) at the European Society for Medical Oncology meeting. The Phase II PICCOLO trial showed a 51.9% overall response rate, with effects lasting 8.25 months. MIRV, an antibody-drug conjugate targeting folate receptor alpha (FRα), offers a less toxic alternative to platinum-based chemotherapy, especially for patients previously treated with PARP inhibitors. The drug is FDA-approved in the U.S. and under evaluation in Europe.
Reference News
Angeles Alvarez Secord, MD, presented promising data on mirvetuximab soravtansine (MIRV) for platinum-sensitive ovarian cancer (PROC) at the European Society for Medical Oncology meeting. The Phase II PICCOLO trial showed a 51.9% overall response rate, with effects lasting 8.25 months. MIRV, an antibody-drug conjugate targeting folate receptor alpha (FRα), offers a less toxic alternative to platinum-based chemotherapy, especially for patients previously treated with PARP inhibitors. The drug is FDA-approved in the U.S. and under evaluation in Europe.